House Panel Provides NCI $1.7 Billion for 1991, Expects Greater Emphasis On Cancer Prevention
In Brief: Megastrol Acetate Still Under FDA Review; Mays Hired For NCI’s Technology Office
NCI Announces Designation Of Comprehensive Center
Columbus CCP Forms New Entity to Administer CCOP
Garfinkel to Retire From ACS; Health to Succeed Him
Fox Chase Biochemist Automates DNA Production
Broder Explains Where R01 Money Has Gone
AACR Honorary Memberships; ASCO Awards
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
